A self-limiting case of atypical neuroleptic malignant syndrome associated with zotepine

Journal of Clinical Psychopharmacology

Volumn 31, Issue 5, 2011, Pages 667-669

  Hsu, Wan Chih ^a   Lin, Shuai Ting ^a   Chen, Cheng Chung ^a   Tsang, Hin Yeung ^a   Huang, Mei Feng ^a  

^a Kaohsiung Kai Suan Psychiatric Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; RISPERIDONE; SULPIRIDE; ZOTEPINE;

ADULT; CASE REPORT; DIAPHORESIS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEVER; HUMAN; HYPONATREMIA; LETTER; LEUKOCYTOSIS; MALE; MUSCLE RIGIDITY; MUTISM; NEUROLEPTIC MALIGNANT SYNDROME; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; SINUS TACHYCARDIA; STUPOR; TACHYCARDIA; TREMOR;

ANTIPSYCHOTIC AGENTS; DIBENZOTHIEPINS; HUMANS; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; SCHIZOPHRENIA, PARANOID;

EID: 80052498238     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31822c2a04     Document Type: Letter

References (17)

1. Picard LS, Lindsay S, Strawn JR, et al. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy. 2008;28:530-535. (Pubitemid 351466464)
2. Zarrouf FA, Bhanot V. Neuroleptic malignant syndrome: don't let your guard down yet. Curr Psychiatry. 2007;6:89-94.
3. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009;23:477-492.
4. Green B. Zotepine: a clinical review. Expert Opin Drug Metab Toxicol. 2009;5: 181-186.
5. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
6. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. (Pubitemid 12149145)
7. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry. 1986;143:1587-1590. (Pubitemid 17196204)
8. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164:870-876. (Pubitemid 46972900)
9. Gudelsky GA, Koenig JI, Meltzer HY. Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology. 1986;25:1307-1313. (Pubitemid 17228209)
10. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000;85:129-135. (Pubitemid 30417228)
11. Satoh H, Fujiwara T, Mori J, et al. Effect of zotepine on fenfluramine-induced hyperthermia in rats. Jpn J Pharmacol. 1984;34:261-263. (Pubitemid 14053731)
12. Myers RD. Neurochemistry of thermoregulation: two negatives make a positive. Brain Res Bull. 1999;50:453-454.
13. Guay DRP. Hyponatremia associated with selective serotonin reuptake inhibitors. Consult Pharm. 2000;15:160-177.
14. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother. 2006;40:1618-1622. (Pubitemid 44330206)
15. Meulendijks D, Mannesse CK, Jansen PA, et al. Antipsychotic-induced hyponatraemia: a systematic review of the published evidence. Drug Saf. 2010;33:101-114.
16. Spivak B, Maline DI, Vered Y, et al. Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome. Acta Psychiatr Scand. 2000;102:226-230. (Pubitemid 30663332)
17. Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res. 1995;29:233-244.